By taking in Celltrion's Eylea biosimilar, Kukje Pharm has further strengthened its position in the domestic ophthalmic disease treatment market.

On the 2nd, Kukje Pharm announced that it has entered into a strategic marketing partnership agreement with Celltrion to commercialize CT-P42 (Eylea biosimilar, aflibercept), an ophthalmic retinal disease treatment developed by Celltrion, in Korea.

Under the agreement, Celltrion will exclusively distribute CT-P42 in Korea to Kukje Pharm, and Kukje Pham will provide patients with access to the high-quality biologic drug in Korea by taking charge of its domestic sales and distribution as soon as CT-P42 is approved by the Ministry of Food